Acceptability and Feasibility in the Context of the IMPROVE Trial in Kenya

PHASE4CompletedINTERVENTIONAL
Enrollment

1,600

Participants

Timeline

Start Date

November 11, 2019

Primary Completion Date

July 31, 2020

Study Completion Date

July 31, 2020

Conditions
Malaria in PregnancyAdherence, Treatment
Interventions
DRUG

Monthly intermittent preventive treatment with dihydroartemisnin-piperaquine

Feasibility study to assess adherence among health providers in antenatal clinics delivering the study interventions in a routine setting and uptake and adherence among pregnant women.

DRUG

Monthly intermittent preventive treatment with sulfadoxine-pyrimethamine

Feasibility study to assess adherence among health providers in antenatal clinics delivering the study interventions in a routine setting and uptake and adherence among pregnant women.

DRUG

Monthly intermittent preventive treatment with dihydroartemisnin-piperaquine with targeted information transfer

Feasibility study to assess adherence to guidelines among health providers in antenatal clinics delivering the study interventions in a routine setting and uptake and adherence among pregnant women.

Trial Locations (1)

40100

Kenya Medical Research Institute, Kisumu

Sponsors
All Listed Sponsors
collaborator

Kenya Medical Research Institute

OTHER

collaborator

Kamuzu University of Health Sciences

OTHER

collaborator

National Institute for Medical Research, Tanzania

OTHER_GOV

collaborator

London School of Hygiene and Tropical Medicine

OTHER

collaborator

University of Bergen

OTHER

collaborator

Kilimanjaro Christian Medical Centre, Tanzania

OTHER

lead

Liverpool School of Tropical Medicine

OTHER